Any CML patient that does have a BCR-ABL over 10% and/or Ph* chromosome over 35% after 6 months of TKI treatment (particularly nilotinib and dasatinib) may be accepted as a failed case and the treatment strategy may be changed. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.